Trospium Chloride Tablet
Product Images NDC 33342-554

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Trospium Chloride (NDC 33342-554). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Macleods Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

666 (Trospium Container 60s)

Packaging label for Trospium Chloride Tablets, USP 20 mg oral tablets. The label shows a 60 tablet count and indicates the product is for prescription use only. Manufactured by Macleods Pharma USA, Inc. in Princeton, NJ, and Macleods Pharmaceuticals Ltd. in Baddi, India. Storage instructions are provided, along with NDC 33342-228-09.*

FDA Label Image

Fig1 (Trospium Fig1)

A line graph depicting plasma concentration (ng/mL) of Trospium Chloride over time (hours post-dose) up to 48 hours. The graph shows a peak in plasma concentration within the first few hours, followed by a gradual decline toward near zero by 48 hours, with error bars indicating variability at each time point.*

FDA Label Image

Fig2 (Trospium Fig2)

A line graph comparing mean (± SE) change over 12 weeks of treatment between Trospium Chloride Tablets (20 mg, N=253) and placebo (N=256). The x-axis is labeled 'Week of Treatment' (weeks 1, 4, 12). The y-axis shows 'Mean (± SE) Change' with values ranging from 0 to -3. Trospium Chloride shows a greater decrease over time compared to placebo, with p-values indicating statistical significance at weeks 4 and 12.*

FDA Label Image

Fig3 (Trospium Fig3)

Line graph comparing mean changes over weeks of treatment between placebo and Trospium Chloride tablets. The x-axis represents weeks of treatment (1, 4, 12), while the y-axis indicates mean change with standard error. Trospium Chloride tablets (253 subjects) show a greater decrease compared to placebo (256 subjects) at weeks 4 and 12, with p-values noted at each time point.*

FDA Label Image

Fig4 (Trospium Fig4)

A line graph comparing the mean change (± SE) over 12 weeks of treatment between placebo and Trospium Chloride tablets groups. The x-axis represents weeks of treatment (1, 4, 12), and the y-axis measures mean change with statistical significance values noted at each time point for Trospium Chloride versus placebo.*

FDA Label Image

Fig5 (Trospium Fig5)

A line graph comparing mean changes over 12 weeks of treatment between Trospium Chloride tablets and placebo groups. The x-axis shows weeks of treatment (1, 4, 12), and the y-axis shows mean change values with standard error bars. Trospium Chloride shows greater mean reduction than placebo at all time points, with p-values <0.001 indicated.*

FDA Label Image

Str (Trospium Str)

Chemical structure diagram of trospium chloride, showing its bicyclic and aromatic ring components along with the chloride ion association.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.